681 related articles for article (PubMed ID: 27436365)
1. Vaccines and immunization strategies for dengue prevention.
Liu Y; Liu J; Cheng G
Emerg Microbes Infect; 2016 Jul; 5(7):e77. PubMed ID: 27436365
[TBL] [Abstract][Full Text] [Related]
2. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
Aguiar M; Stollenwerk N; Halstead SB
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
[TBL] [Abstract][Full Text] [Related]
3. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
4. Targets and strategies for vaccine development against dengue viruses.
Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
[TBL] [Abstract][Full Text] [Related]
5. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
6. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Osorio JE; Wallace D; Stinchcomb DT
Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice.
Lu H; Xu XF; Gao N; Fan DY; Wang J; An J
Mol Immunol; 2013 Jun; 54(2):109-14. PubMed ID: 23270684
[TBL] [Abstract][Full Text] [Related]
8. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
[TBL] [Abstract][Full Text] [Related]
9. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
Galula JU; Salem GM; Chang GJ; Chao DY
Hum Vaccin Immunother; 2019; 15(10):2328-2336. PubMed ID: 31314657
[TBL] [Abstract][Full Text] [Related]
10. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
[TBL] [Abstract][Full Text] [Related]
11. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
12. Vaccines licensed and in clinical trials for the prevention of dengue.
Torresi J; Ebert G; Pellegrini M
Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864
[TBL] [Abstract][Full Text] [Related]
13. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
14. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
[TBL] [Abstract][Full Text] [Related]
15. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
16. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
[TBL] [Abstract][Full Text] [Related]
17. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.
Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E
J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638
[TBL] [Abstract][Full Text] [Related]
18. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
Martinez DR; Metz SW; Baric RS
Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
[TBL] [Abstract][Full Text] [Related]
19. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.
Halstead SB
Am J Trop Med Hyg; 2016 Oct; 95(4):741-745. PubMed ID: 27352870
[TBL] [Abstract][Full Text] [Related]
20. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
